# US 2022/0031783 A1 · Phenylethanoid Glycoside Extract from Acanthus Ilicifolius L., Preparation Method thereof and Use as Anti-liver Injury Medicament

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031783 A1
- Document ID: US20220031783A1
- Status: Published application
- Kind: A1
- Application number: 17/485,995
- Filed: 2021-09-27
- Published: 2022-02-03
- Earliest claimed: 2019-12-12
- Assignees: Ocean University of China
- Applicants: Ocean University of China
- Inventors: Changyun WANG; Changlun SHAO; Mengqi ZHANG; Hong BAI; Xia REN; Shijun YUE; Lanting XIN; Qing ZHAO
- Web page: https://patentgrep.com/patent/US20220031783A1

## CPC

- A61K 36/19: Acanthaceae (Acanthus family)
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/7032: attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K 2236/15: involving mechanical treatment, e.g. chopping up, cutting or grinding
- A61K 2236/17: involving drying, e.g. sun-drying or wilting
- A61K 2236/333: using mixed solvents, e.g. 70% EtOH
- A61K 2236/51: Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a phenylethanoid glycoside extract from the plant A. ilicifolius L., a preparation method thereof, and its use as an anti-liver injury medicament. The preparation method of the phenylethanoid glycoside extract comprises following steps: pulverizing dried whole plant Acanthus ilicifolius L. and passing through 20-30 mesh sieve to obtain Acanthus ilicifolius L. powder, adding 50%-95% ethanol solution whose mass is 8-20 times of the powder, soaking and extracting under reflux, filtering and collecting extract of the powder, and extracting a filter residue under reflux with 50%-95% ethanol solution whose mass is 8-10 times of the filter residue and collecting extract of the filter residue, combining, concentrating and subjecting to macroporous resin column chromatography, eluting successively by 10%, 30% and 50% ethanol solutions for four column volumes, respectively, collecting fraction eluted by the 50% ethanol solution and drying to obtain the phenylethanoid glycoside extract.

## Claims

### Claim 1

A phenylethanoid glycoside extract, wherein the phenylethanoid glycoside extract is prepared by a method comprising following steps:
pulverizing dried whole plant Acanthus ilicifolius L. and passing through a 20-30 mesh sieve to obtain Acanthus ilicifolius L. powder, adding a 50%-95% ethanol solution whose mass is 8-20 times of the powder, soaking for 1-3 h and then extracting under reflux for 2-4 h, filtering and collecting an extract of the powder, and then extracting a filter residue under reflux for 1.5-2 h with 50%-95% ethanol solution whose mass is 8-10 times of the filter residue and collecting an extract of the filter residue, combining the extract of the powder and the extract of the filter residue, concentrating and subjecting to macroporous resin column chromatography, eluting successively by 10%, 30% and 50% ethanol solutions for four column volumes, respectively, collecting a fraction eluted by the 50% ethanol solution and drying to obtain the phenylethanoid glycoside extract, wherein the percentages of ethanol solutions are all volume percentages.

### Claim 2 (depends on 1)

The phenylethanoid glycoside extract of claim 1, wherein a content of phenylethanoid glycoside compounds in the phenylethanoid glycoside extract is more than 70 wt %.

### Claim 3 (depends on 1)

The phenylethanoid glycoside extract of claim 1, wherein a content of phenylethanoid glycoside compounds in the phenylethanoid glycoside extract is 73.78±2.00 wt %.

### Claim 4 (depends on 1)

The phenylethanoid glycoside extract of claim 1, wherein the phenylethanoid glycoside extract comprises at least four compounds of acteoside, isocrenatoside, isoacteoside and p-coumaric acid.

### Claim 5 (depends on 1)

The phenylethanoid glycoside extract of claim 1, wherein an HPLC profile of the phenylethanoid glycoside extract is substantially consistent with FIG. 2.

### Claim 6 (depends on 1)

The phenylethanoid glycoside extract of claim 1, wherein a stationary phase of the macroporous resin column chromatography is D101 type or AB-8 type macroporous resin.

### Claim 7 (depends on 1)

A method for increasing activity of superoxide dismutase (SOD) in a subject, comprising administering an effective dose of the phenylethanoid glycoside extract of claim 1 to the subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein a content of phenylethanoid glycoside compounds in the phenylethanoid glycoside extract is more than 70 wt %.

### Claim 9 (depends on 7)

The method of claim 7, wherein a content of phenethanol glycoside compounds in the phenylethanoid glycoside extract is 73.78±2.00 wt %.

### Claim 10 (depends on 7)

The method of claim 7, wherein the phenylethanoid glycoside extract comprises at least four compounds of acteoside, isocrenatoside, isoacteoside and p-coumaric acid.

### Claim 11 (depends on 7)

The method of claim 7, wherein an HPLC profile of the phenylethanoid glycoside extract is substantially consistent with FIG. 2.

### Claim 12 (depends on 7)

The method of claim 7, wherein the stationary phase of the macroporous resin column chromatography is D101 type or AB-8 type macroporous resin.

### Claim 13 (depends on 1)

A method for reducing a level of lipid peroxide malondialdehyde (MDA) in a subject, comprising administering an effective dose of the phenylethanoid glycoside extract according to claim 1 to the subject.

### Claim 14 (depends on 13)

The method of claim 13, wherein a content of phenethanol glycoside compounds in the phenylethanoid glycoside extract is more than 70 wt %.

### Claim 15 (depends on 13)

The method of claim 13, wherein a content of phenylethanoid glycoside compounds in the phenylethanoid glycoside extract is 73.78±2.00 wt %.

### Claim 16 (depends on 13)

The method of claim 13, wherein the phenylethanoid glycoside extract contains at least four compounds of acteoside, isocrenatoside, isoacteoside and p-coumaric acid.

### Claim 17 (depends on 13)

The method of claim 13, wherein an HPLC profile of the phenylethanoid glycoside extract is substantially consistent with FIG. 2.

### Claim 18 (depends on 13)

The method according to claim 13, wherein the stationary phase of the macroporous resin column chromatography is D101 type or AB-8 type macroporous resin.
